New Implications from Long-Term Outcomes of Perioperative Therapy in Resectable Pancreatic Cancer

The results of long-term follow-up studies of the adjuvant PRODIGE24 trial comparing FOLFIRINOX with gemcitabine and the ESPAC4 trial of gemcitabine-capecitabine versus gemcitabine have consolidated and expanded the applicability of adjuvant chemotherapy.